Page last updated: 2024-12-04

1-aminobenzotriazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 1-Aminobenzotriazole (ABT): A Versatile Reagent in Research

1-Aminobenzotriazole (ABT) is a heterocyclic organic compound with a unique chemical structure that makes it a versatile tool in various research fields. Here's a breakdown of its characteristics and importance:

**Structure and Properties:**

* **Formula:** C6H6N4
* **Appearance:** White to off-white solid
* **Key features:**
* Contains a triazole ring with an amino group attached at the 1-position
* Exhibits strong nucleophilic properties
* Can act as a base and a ligand
* Possesses excellent stability in both acidic and basic conditions

**Applications in Research:**

**1. Organic Synthesis:**

* **Protecting Group for Carboxylic Acids:** ABT can be used to form stable benzotriazole esters, protecting carboxylic acids from unwanted reactions during multi-step synthesis.
* **Coupling Reactions:** ABT is employed in various coupling reactions, including peptide synthesis and the synthesis of amides, esters, and other functional groups. It helps to activate carboxylic acids for these reactions.
* **Catalyst in Carbon-Carbon Bond Formation:** ABT has been shown to catalyze various carbon-carbon bond-forming reactions, particularly those involving organometallic reagents.

**2. Analytical Chemistry:**

* **Spectrophotometric Reagent:** ABT can form colored complexes with various metal ions, making it useful for spectrophotometric analysis and determining metal concentrations.
* **Chromatographic Analysis:** ABT can be used as a derivatizing agent for improving the separation and detection of analytes in various chromatographic techniques.

**3. Material Science:**

* **Polymer Synthesis:** ABT can be incorporated into polymers, modifying their properties and enhancing their functionality.
* **Nanotechnology:** ABT has been explored in the synthesis of nanomaterials, contributing to the development of advanced materials with specific properties.

**4. Biological Research:**

* **Inhibitor of Biological Targets:** ABT can act as an inhibitor for various biological targets, including enzymes and receptors. Its inhibitory activity makes it useful for studying various biological processes.
* **Drug Development:** ABT is a scaffold molecule that can be modified to create new drug candidates with improved biological activity and pharmacological properties.

**5. Other Applications:**

* **Corrosion Inhibitors:** ABT can be used as a corrosion inhibitor for metals due to its ability to form protective layers on metal surfaces.
* **Antioxidant:** ABT has antioxidant properties, potentially protecting materials from oxidative damage.

**Overall, 1-Aminobenzotriazole is a versatile and important compound with a wide range of applications in diverse research fields. Its unique chemical structure and properties make it a valuable tool for organic synthesis, analytical chemistry, material science, biological research, and other applications.**

Cross-References

ID SourceID
PubMed CID1367
CHEMBL ID101168
SCHEMBL ID94751
MeSH IDM0102636

Synonyms (73)

Synonym
1h-1,2,3-benzotriazol-1-ylamine
benzotriazol-1-amine
NCI60_019729
nsc656987
nsc-656987
EU-0100056
nsc 114498
1-abtz
1h-benzotriazol-1-amine
NCGC00015056-01
lopac-a-3940
LOPAC0_000056
1614-12-6
nsc-114498
nsc114498
inchi=1/c6h6n4/c7-10-6-4-2-1-3-5(6)8-9-10/h1-4h,7h
1h-1,2,3-benzotriazol-1-amine
AK-830/25033013
MLS001056764
smr000326746
1-aminobenzotriazole
NCGC00093570-02
NCGC00093570-01
NCGC00015056-02
A 3940
abt; 1-benzotriazolamine
1-benzotriazolamine
NCGC00015056-04
CHEMBL101168 ,
bdbm50106744
FT-0691063
AKOS001013369
A3576
1h-benzo[d][1,2,3]triazol-1-amine
HMS3260K13
M01240
CCG-204151
unii-9eff75bj1o
9eff75bj1o ,
HMS2235A14
NCGC00015056-03
MS-1148
benzotriazolylamine
LP00056
BRD-K19037540-001-07-8
S10070
S6886
HMS3374C01
SCHEMBL94751
NCGC00260741-01
tox21_500056
JCXKHYLLVKZPKE-UHFFFAOYSA-N
Q-102063
DTXSID80167140
mfcd00132902
benzotriazol-1-ylamine
1-benzotriazolylamine
1-aminobenzotriazole, >=98.0% (gc)
sr-01000075675
SR-01000075675-1
SY008977
Q26841296
abt;3-aminobenzotriazole
HY-103389
CS-0027797
1h-benzotriazole, 1-amino-
1-amino-1,2,3-benzotriazole
1h-benzo(d)(1,2,3)triazol-1-amine
3-aminobenzotriazole
SDCCGSBI-0050044.P002
NCGC00015056-08
EN300-6743522
Z56788890

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Precocene II was also toxic to 72-h cultures, although the effect of the serum-free medium was attenuated."( Toxicity of precocene II in rat hepatocyte cultures: effects of serum and culture time.
Fry, JR; Hammond, AH, 1994
)
0.29
"Precocene II was more toxic in 24 hour cultures than in 72 hour cultures of rat hepatocytes."( Mechanism of toxicity of precocene II in rat hepatocyte cultures.
Fry, JR; Garle, MJ; Hammond, AH, 1995
)
0.29
" This study examines whether acetaminophen is toxic to sinusoidal endothelial cells (SEC), which might lead to microcirculatory disruption."( Sinusoidal endothelial cells as a target for acetaminophen toxicity. Direct action versus requirement for hepatocyte activation in different mouse strains.
Bart, JA; DeLeve, LD; Kaplowitz, N; Shulman, HM; van der Hoek, A; Wang, X, 1997
)
0.3
" These data demonstrate that the parent forms of leflunomide and A77 1726 are more toxic to hepatocytes than their poorly characterized metabolites, indicating that the metabolic process of leflunomide is a detoxification step rather than an initiating event leading to toxicity."( Hepatic cytochrome P450s attenuate the cytotoxicity induced by leflunomide and its active metabolite A77 1726 in primary cultured rat hepatocytes.
Greenhaw, J; Salminen, WF; Shi, Q; Yang, X, 2011
)
0.37
" AFB was selective toxic towards the human hepatocytes and relatively noncytotoxic towards 3T3 cells both in the presence and absence of the hepatocytes."( Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1, cyclo
LaForge, YS; Li, AP; Uzgare, A, 2012
)
0.38

Pharmacokinetics

ExcerptReferenceRelevance
" The oral pharmacokinetic profiles of ABT were generated in rats, dogs, and monkeys in the dose range of 5 to 200 mg/kg."( Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys.
Balani, SK; He, B; Lee, FW; Liu, Z; Yang, TJ; Zhu, T, 2002
)
0.61
" The projected P450 inactivations at the plasma Cmax of ABT agreed with the inhibitions of P450-mediated AP clearance observed in vivo."( Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling.
Balani, SK; Cardoza, K; Gan, LS; Lee, FW; Li, P; Mu, DX; Nguyen, J; Wu, JT; Zeng, H, 2004
)
0.62
"Since drug candidates with low oral systemic exposure may be due to either or both absorption and metabolism factors, determining what factors limit the oral systemic exposure is not always obvious in a single in-vivo pharmacokinetic (PK) assay."( The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens.
Caldwell, GW; Cotto, C; Hageman, W; Hall, J; Hasting, B; Jones, W; Masucci, JA; Ritchie, DM,
)
0.13
" The pharmacokinetic parameters of ABT did not change when it was dosed along with CZX (oral and IV), indicating that either CZX or OH-CZX had no effect on disposition of ABT."( Effect of 1-aminobenzotriazole on the in vitro metabolism and single-dose pharmacokinetics of chlorzoxazone, a selective CYP2E1 substrate in Wistar rats.
Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Srinivas, NR, 2005
)
0.73
" ABT administration decreased the initial systemic exposure of orally administered NVS-CRF38 and increased Tmax 40-fold, suggesting gastric retention and delayed oral absorption."( 1-Aminobenzotriazole modulates oral drug pharmacokinetics through cytochrome P450 inhibition and delay of gastric emptying in rats.
Lavan, P; Medhurst, S; Sohal, B; Stringer, RA; Tigani, B; Weber, E, 2014
)
1.85
"AMG 517 or 1-aminobenzotriazole were quantified by LC-MS/MS from low blood/plasma volumes for rat pharmacokinetic (PK) characterization in order to qualify manual/automated dried blood spot (DBS) sampling and plasma separation capillary sampling."( Evaluation of matrix microsampling methods for therapeutic drug candidate quantification in discovery-stage rodent pharmacokinetic studies.
Almon, V; James, CA; Meyer, J; Pham, R; Ponce, M; Primack, R; Retter, MW; Salyers, KL; Soto, M; Wagner, M, 2014
)
0.79
"In pharmacokinetic evaluation of mice, using serial sampling methods rather than a terminal blood sampling method could reduce the number of animals needed and lead to more reliable data by excluding individual differences."( Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction.
Nezasa, K; Ogawa, K; Shimizu, R; Takai, N; Tanaka, Y; Watanabe, A; Watari, R; Yamaguchi, Y, 2015
)
0.42
" Non-compartmental pharmacokinetic analysis was performed using PKsolver."( Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model.
Abla, N; Haas, H; Keiser, J; Reimers, N; Spangenberg, T; Vargas, M, 2017
)
0.46

Compound-Compound Interactions

ExcerptReferenceRelevance
" In addition, using serial sampling methods can be valuable for evaluation of the drug-drug interaction (DDI) potential of drug candidates."( Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction.
Nezasa, K; Ogawa, K; Shimizu, R; Takai, N; Tanaka, Y; Watanabe, A; Watari, R; Yamaguchi, Y, 2015
)
0.42
"The purpose of the present study is to demonstrate a useful approach (isotope-IV method) for analyzing drug-drug interactions (DDIs) following the oral administration of drugs using stable isotope-labeled compounds."( Quantitative analysis of pharmacokinetic profiles of verapamil and drug-drug interactions induced by a CYP inhibitor using a stable isotope-labeled compound.
Higashino, H; Kataoka, M; Kojima, C; Minami, K; Mutaguchi, K; Sakuma, S; Togashi, K; Ueda, K; Yamashita, S, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" The oral bioavailability of CZX was approximately 71% when dosed alone and reached 100% under pre-treatment with ABT."( Effect of 1-aminobenzotriazole on the in vitro metabolism and single-dose pharmacokinetics of chlorzoxazone, a selective CYP2E1 substrate in Wistar rats.
Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Srinivas, NR, 2005
)
0.73
"Preliminary studies in our laboratory demonstrated low oral bioavailability of Drug X in male Sprague Dawley rats."( The use of 1-aminobenzotriazole in differentiating the role of CYP-mediated first pass metabolism and absorption in limiting drug oral bioavailability: a case study.
Brodfuehrer, J; Buchholz, L; Clark, A; El-Kattan, AF; Poe, J; Thomas, HV, 2008
)
0.74
"To clarify the causes of low oral bioavailability (BA) of drugs in cynomolgus monkeys, the experimental method to evaluate the drug permeability and the metabolism in the intestine of cynomolgus monkeys was established."( Investigation of the intestinal permeability and first-pass metabolism of drugs in cynomolgus monkeys using single-pass intestinal perfusion.
Igeta, K; Suzuki, N; Takahashi, M; Washio, T; Yamashita, S, 2010
)
0.36
" Pharmacokinetic experiments in rats showed that bioavailability was much lower than anticipated and increased following pretreatment with the nonspecific cytochrome P450 (CYP) inhibitor 1-aminobenzotriazole, presumably by inhibition of intestinal metabolism."( Presystemic metabolism of AZ'0908, a novel mPGES-1 inhibitor: an in vitro and in vivo cross-species comparison.
Bueters, T; Bylund, J, 2013
)
0.58
"The impact of gastrointestinal (GI) processing and first pass metabolism on danazol oral bioavailability (BA) was evaluated after administration of self-emulsifying drug delivery systems (SEDDS) in the rat."( An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.
Anby, MU; Benameur, H; Feeney, OM; Nguyen, TH; Porter, CJ; Pouton, CW; Williams, HD; Yeap, YY, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" The rats were killed at 1, 6, 24, 48 or 72 h after dosing and the concentration of total radioactivity in various tissues and organs measured."( Distribution of 1-aminobenzotriazole in male rats after administration of an oral dose.
Chang, D; Garland, W; Henderson, L; Mortillo, M; Town, C, 1993
)
0.63
" Plasma ALT activities and quantitation of liver injury by light microscopy at 48 h after CHCl(3) dosing indicated that all three treatments were equally effective at protecting the liver."( Hepatoprotection by dimethyl sulfoxide. III. Role of inhibition of the bioactivation and covalent bonding of chloroform.
Begay, CK; Gandolfi, AJ; Lind, RC, 2000
)
0.31
" Based on these data in rats, dogs, and monkeys, and the established safety profile of ABT in rats dosed up to 100 mg/kg, a pretreatment at 2 h with a single oral dose of ABT at 100 mg/kg in rats (providing 93% inhibition) and 20 mg/kg in dogs and monkeys effectively inhibited the clearance of the probe compound."( Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys.
Balani, SK; He, B; Lee, FW; Liu, Z; Yang, TJ; Zhu, T, 2002
)
0.61
" The oral bioavailability of CZX was approximately 71% when dosed alone and reached 100% under pre-treatment with ABT."( Effect of 1-aminobenzotriazole on the in vitro metabolism and single-dose pharmacokinetics of chlorzoxazone, a selective CYP2E1 substrate in Wistar rats.
Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Srinivas, NR, 2005
)
0.73
" The MDZ bioavailablity in rats dosed orally and in rats dosed intravenously with ABT is 58."( In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance.
Fisher, MB; Foti, RS; Strelevitz, TJ, 2006
)
0.61
" In rats dosed intravenously with [(14)C]-1, approximately 91% of the radioactivity was recovered in bile over 48 h, with 85% accounted for in the first 4-h samples."( Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats.
Baillie, TA; Bleasby, K; Chen, Q; Colletti, A; Dean, DC; Evers, R; Hafey, M; Hagmann, WK; Lanza, TJ; Lin, LS; Magriotis, PA; Stearns, RA; Tang, W; Teffera, Y, 2008
)
0.35
" Oral dosing of Drug X to rats resulted in low oral bioavailability (19%)."( The use of 1-aminobenzotriazole in differentiating the role of CYP-mediated first pass metabolism and absorption in limiting drug oral bioavailability: a case study.
Brodfuehrer, J; Buchholz, L; Clark, A; El-Kattan, AF; Poe, J; Thomas, HV, 2008
)
0.74
" Administration of radio-labeled TIC in combination with BSO resulted in significantly higher covalent binding to rat liver proteins than that observed after sole dosing of radio-labeled TIC."( Ticlopidine-induced hepatotoxicity in a GSH-depleted rat model.
Atsumi, R; Izumi, T; Nakazawa, T; Okazaki, O; Saji, H; Shimizu, S; Sudo, K, 2011
)
0.37
" A dose-response curve for each of the suicide inhibitors was developed."( Inhibition of cytochromes P450 and the hydroxylation of 4-monochlorobiphenyl in whole poplar.
Lehmler, HJ; Schnoor, JL; Zhai, G, 2013
)
0.39
" In vivo ABT administration by an osmotic pump offers an effective approach for longer-term P450 inhibition in mice and avoids the necessity for multiple dosing of the inhibitor."( Application of Osmotic Pumps for Sustained Release of 1-Aminobenzotriazole and Inhibition of Cytochrome P450 Enzymes in Mice: Model Comparison with the Hepatic P450 Reductase Null Mouse.
Ferreira, S; Ronseaux, S; Rose, J; Stringer, RA, 2016
)
0.68
" An effective dosing regimen of ABT for a multiple-administration study is needed to conduct pharmacological studies for proof-of-concept, although it has been established for single-administration study, to characterize the pharmacokinetics of drug candidates."( In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice.
Mayumi, K; Nishimura, K; Osaki, H; Watanabe, A, 2016
)
0.72
"Accurate prediction of drug target activity and rational dosing regimen design require knowledge of drug concentrations at the target."( Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport.
Korzekwa, K; Kulkarni, P; Nagar, S, 2016
)
0.43
" Dose-response studies with racemic PZQ with or without addition of an irreversible pan-cytochrome P450 (CYP) inhibitor, 1-aminobenzotriazole (ABT), were performed."( Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model.
Abla, N; Haas, H; Keiser, J; Reimers, N; Spangenberg, T; Vargas, M, 2017
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency5.17350.000811.382244.6684AID686978
Microtubule-associated protein tauHomo sapiens (human)Potency0.02820.180013.557439.8107AID1460
ThrombopoietinHomo sapiens (human)Potency1.00000.02517.304831.6228AID917; AID918
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency2.67280.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency31.62280.00207.533739.8107AID891
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
flap endonuclease 1Homo sapiens (human)Potency21.19230.133725.412989.1251AID588795
gemininHomo sapiens (human)Potency16.36010.004611.374133.4983AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency6.30960.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.03160.00106.000935.4813AID943
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency112.20203.981146.7448112.2020AID720711
GABA theta subunitRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)0.45000.00011.753610.0000AID54784
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)10.50000.00002.015110.0000AID54588
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)42.90000.00002.800510.0000AID54400
Cytochrome P450 4Z1Homo sapiens (human)IC50 (µMol)83.00005.90006.30006.7000AID1607229; AID1607230
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 4Z1Homo sapiens (human)
lauric acid metabolic processCytochrome P450 4Z1Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (35)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 4Z1Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 4Z1Homo sapiens (human)
heme bindingCytochrome P450 4Z1Homo sapiens (human)
fatty acid in-chain hydroxylase activityCytochrome P450 4Z1Homo sapiens (human)
aromatase activityCytochrome P450 4Z1Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneCytochrome P450 4Z1Homo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (72)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1725272Inhibition of CYP3A4 in HBV-infected human HepaRG cells at 10 mM using luciferin-IPA as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days in presence of 50 uM2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1725300Inhibition of CYP1A2 in HBV-infected human HepaRG cells at 0.2 to 20 mM using luciferin-1A2 as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1725276Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 10 mM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days in presence of 50 uM S2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1725261Antiviral activity against Hepatitis B virus infected in human HepaRG cells assessed as reduction in HbsAg secretion level at 10 mM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubat2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725289Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 10 mM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by treat2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725301Antiviral activity against Hepatitis B virus infected in human primary hepatocytes assessed as reduction in HbsAg secretion level at 10 mM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further 2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID54588Inhibition of recombinant human Cytochrome P450 2D62001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.
AID1725271Inhibition of CYP3A4 in HBV-infected human HepaRG cells at 10 mM using luciferin-IPA as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by tre2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725266Inhibition of CYP2C9 in HBV-infected human primary hepatocytes cells at 0.2 to 20 mM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days th2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1862035Inhibition of rat CYP3A4 in rat liver microsomes assessed as inhibition of midazolam metabolism using midazolam as substrate at 10 uM incubated for 10 mins relative to control2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Discovery of benzyloxyphenyl- and phenethylphenyl-imidazole derivatives as a new class of ante-drug type boosters.
AID1725305Antiviral activity against Hepatitis B virus infected in human primary hepatocytes assessed as reduction in HbsAg secretion level at 10 mM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further 2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725264Inhibition of CYP3A4 in HBV-infected human primary hepatocytes at 0.2 to 20 mM using luciferin-IPA as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then f2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725291Inhibition of CYP1A2 in HBV-infected human HepaRG cells at 10 mM using luciferin-1A2 as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by tre2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725279Inhibition of CYP1A2 in HBV-infected human HepaRG cells at 10 mM using luciferin-1A2 as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by tre2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725288Inhibition of CYP3A4 in HBV-infected human HepaRG cells at 10 mM using luciferin-IPA as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by tre2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID54784Inhibition of recombinant human Cytochrome P450 3A42001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.
AID1725293Inhibition of CYP1A2 in HBV-infected human HepaRG cells at 10 mM using luciferin-1A2 as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days by P450-Glo chemilum2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1607231Ratio of IC50 for inhibition of CYP4Z1 (unknown origin) in human HepG2 cell membranes transduced with lentiviral vector using luciferin-benzyl ether as substrate incubated for 5 mins followed by NADPH addition and measured after 20 mins to IC50 for inhibi2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.
AID1725287Inhibition of CYP3A4 in HBV-infected human HepaRG cells at 10 mM using luciferin-IPA as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days by P450-Glo chemilum2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725268Inhibition of CYP1A2 in HBV-infected human primary hepatocytes at 0.2 to 20 mM using luciferin-1A2 as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then f2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1211495Inhibition of human CYP2E1 assessed as chlorzoxazone 6-hydroxylase activity at 2.5 mM after 72 hrs preincubation by HPLC analysis (RVb = 100%)2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen.
AID1725294Cytotoxicity against human HepaRG cells infected with HBV assessed as reduction in cell viability at 0.2 to 20 mM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1725275Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 10 mM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by treat2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725259Cytotoxicity against human HepaRG cells infected with HBV assessed as reduction in cell viability at 10 mM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then follow2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725306Cytotoxicity against human primary hepatocytes infected with HBV assessed as reduction in cell viability at 10 mM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725290Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 10 mM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days by P450-Glo chemilumin2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1607230Inhibition of CYP4Z1 (unknown origin) in human HepG2 cell membranes transduced with lentiviral vector using luciferin-benzyl ether as substrate incubated for 5 mins followed by NADPH addition and measured after 20 mins by P450-glo luciferase based lumines2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.
AID1725296Inhibition of CYP3A4 in HBV-infected human HepaRG cells at 0.2 to 20 mM using luciferin-IPA as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725280Inhibition of CYP1A2 in HBV-infected human HepaRG cells at 10 mM using luciferin-1A2 as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days in presence of 50 uM2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1607229Inhibition of CYP4Z1 (unknown origin) in human HepG2 cell membranes transduced with lentiviral vector using luciferin-benzyl ether as substrate preincubated with NADPH for 30 mins followed by substrate addition and measured after 10 mins by P450-glo lucif2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.
AID54400Inhibition of recombinant human Cytochrome P450 2C92001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.
AID1725303Cytotoxicity against human primary hepatocytes infected with HBV assessed as reduction in cell viability at 10 mM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725298Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 0.2 to 20 mM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed b2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (210)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (3.81)18.7374
1990's46 (21.90)18.2507
2000's65 (30.95)29.6817
2010's79 (37.62)24.3611
2020's12 (5.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.59 (24.57)
Research Supply Index5.41 (2.92)
Research Growth Index5.24 (4.65)
Search Engine Demand Index36.43 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other222 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]